Gopal, AK;
Popat, R;
Mattison, RJ;
Menne, T;
Bloor, A;
Gaymes, T;
Khwaja, A;
... Mufti, GJ; + view all
(2021)
A Phase I trial of talazoparib in patients with advanced hematologic malignancies.
International Journal of Hematologic Oncology
, 10
(3)
10.2217/ijh-2021-0004.
Preview |
Text
ijh-2021-0004.pdf - Published Version Download (445kB) | Preview |
Abstract
Aim: The objective of this study was to establish the maximum tolerated dose (MTD), safety, pharmacokinetics, and anti-leukemic activity of talazoparib. Patients & methods: This Phase I, two-cohort, dose-escalation trial evaluated talazoparib monotherapy in advanced hematologic malignancies (cohort 1: acute myeloid leukemia/myelodysplastic syndrome; cohort 2: chronic lymphocytic leukemia/mantle cell lymphoma). Results: Thirty-three (cohort 1: n = 25; cohort 2: n = 8) patients received talazoparib (0.1-2.0 mg once daily). The MTD was exceeded at 2.0 mg/day in cohort 1 and at 0.9 mg/day in cohort 2. Grade ≥3 adverse events were primarily hematologic. Eighteen (54.5%) patients reported stable disease. Conclusion: Talazoparib is relatively well tolerated in hematologic malignancies, with a similar MTD as in solid tumors, and shows preliminary anti leukemic activity.Clinical trial registration: NCT01399840 (ClinicalTrials.gov).
| Type: | Article |
|---|---|
| Title: | A Phase I trial of talazoparib in patients with advanced hematologic malignancies |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.2217/ijh-2021-0004 |
| Publisher version: | https://www.futuremedicine.com/doi/full/10.2217/ij... |
| Language: | English |
| Additional information: | This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | BRCA1/2 mutations, DNA damage response, hematologic malignancy, poly(ADP-ribose) polymerase inhibition, talazoparib |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10139844 |
Archive Staff Only
 |
View Item |
